Videos

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.

Michael Wang, MD, discusses where unmet needs still exist for patients with relapsed/refractory mantle cell lymphoma.

Petros Grivas, MD, PhD, discusses the design and end points of the phase 2 KEYNOTE-057 trial.

Ruchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.

Key opinion leaders on breast cancer management share insight on the evolving role of antibody drug conjugates and their potential impact on care.

Following her review of TROPiCS-02, Joyce O’Shaughnessy, MD, shares data from the DESTINY-Breast04 study of T-DXd in HER2-low metastatic breast cancer.

Prerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.

Manmeet Ahluwalia, MD, discusses brain metastases in patient with biomarker-driven lung cancer and outcomes of these patients.

A key opinion leader in the field of renal cell carcinoma offers clinical insight on treatment sequencing strategies.

A comprehensive review of second-line treatment options for patients with clear cell renal cell carcinoma.

A phase 3 study of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma is discussed by Binod Dhakal, MD, MS.

Jonathan C. Trent, MD, PhD, discusses the methods, design, and results from the INTRIGUE study in advanced gastrointestinal stromal tumor.

Prerna Mewawalla, MD, discusses how she approaches the choice of therapy for relapsed/refractory multiple myeloma now that many different options are available for patients.

Dr Jamie L. Koprivnikar describes her general approaches to diagnosing and risk stratifying patients with myelodysplastic syndrome, and how she differentiates high-risk and low-risk disease.

Jamie L. Koprivnikar, MD, presents the case of a 72-year-old woman diagnosed with single lineage dysplasia myelodysplastic syndrome and shares her initial impressions.

Eytan M. Stein, MD, discusses trials evaluating Menin inhibitors for patients with acute leukemia and unmet needs that persist in the space.

Johannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia/

Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.

The panel debates the various treatment options and comments on when they prefer each one.

Se-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Marcia S. Brose, MD, PhD, FASCO, discusses trials LIBRETTO program leading up to LIBRETTO-531.

Eric A. Singer, MD, MS, discusses future developments that could improve the utilization of adjuvant therapy for high-risk renal cell carcinoma.

Expert Joyce O’Shaughnessy, MD, reviews data from the TROPiCS-02 study of sacituzumab govitecan in HR+/HER2- metastatic breast cancer.

Expert perspectives on a second patient case of unmutated metastatic breast cancer and available treatment strategies in this setting.

Sara Tolaney, MD, MPH, discusses key takeaways from the TROPiCS-02 study of sacituzumab govitecan-hziy for patients with hormone receptor-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.

Antonio Ucar, MD, explains the rationale behind the phase 3 Peak study of bezuclastinib plus sunitinib in patients with gastrointestinal stromal tumors being treated in the second-line setting.

Robert J. Motzer, MD, provides insights on factors that influence treatment decisions for patients with clear cell renal cell carcinoma.

Continuing discussion on advanced renal cell carcinoma, Robert J. Motzer, MD, reviews recent clinical trial data presented at ASCO 2023 and KCRS 2023.

Eytan M. Stein, MD, reviews recent follow-up data from the IMerge trial investigating imetelstat in patients with lower-risk myelodysplastic syndrome.

Ann LaCasce, MD, MMSc, discusses the effects that chemotherapy drug shortages may have on clinical trials and patient accrual.